您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2024, Vol. 62 ›› Issue (6): 54-64.doi: 10.6040/j.issn.1671-7554.0.2024.0074

• 临床医学 • 上一篇    

大于10 mm甲状腺乳头状癌侧颈区淋巴结转移预测

林雨洋,王蓓,李菲   

  • 发布日期:2024-07-15
  • 通讯作者: 王蓓. E-mail:wangbei1224@126.com

Prediction of lateral lymph node metastasis in papillary thyroid carcinoma larger than 10 mm

LIN Yuyang, WANG Bei, LI Fei   

  1. Department of Medical Ultrasound, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, Shandong, China
  • Published:2024-07-15

PDF (PC)

44

摘要： 目的 预测直径>10 mm(非T1a期)甲状腺乳头状癌(papillary thyroid carcinoma, PTC)患者侧颈区淋巴结转移(lateral lymph node metastasis, LLNM),并分析其转移模式。 方法 回顾性分析166例行甲状腺切除术合并侧颈区清扫术且病灶直径>10 mm的PTC患者资料;分析其临床病理特征及侧颈部各分区淋巴结转移模式。收集临床病理、超声特征及实验室检查结果等资料,利用单因素、多因素Logistic回归分析来评估与LLNM相关因素;在此结果上建立列线图模型,采用受试者工作特征(receiver operating characteristic, ROC)曲线评估其模型的准确性。 结果 LLNM最常见于Ⅲ区(38.1%),且两个区域转移模式(42.2%)最常见。当病灶位于腺体不同位置时,淋巴结转移模式差异无统计学意义(P>0.05)。多因素Logistic回归结果显示,病灶位置、游离三碘甲腺原氨酸(free triiodothyronine, FT3)、促甲状腺激素(thyroid stimulating hormone, TSH)、甲状腺过氧化物酶抗体(thyroid peroxidase antibodies, TPOAB)水平及中央区淋巴结转移(central lymph node metastasis, CLNM)数目均是LLNM的独立危险因素。列线图预测模型的曲线下面积为0.851,提示模型诊断准确度较高。 结论 基于临床病理、超声特征及实验室结果(CLNM数目、病灶位置、FT3、TSH及TPOAB水平)的列线图模型对预测直径>10 mm PTC患者LLNM表现良好,可用于临床应用指导。

关键词: 甲状腺乳头状癌, 侧颈区淋巴结转移, 中央区淋巴结转移, 促甲状腺激素, 甲状腺过氧化物酶抗体, 游离三碘甲状腺原氨酸

Abstract: Objective To predict the occurrence of lateral lymph node metastasis(LLNM)in papillary thyroid carcinoma(PTC)larger than 10 mm in diameter(non-T1A stage)and analyze the metastatic pattern. Methods A retrospective analysis was conducted on 166 PTC patients with the foci diameters larger than 10 mm who underwent thyroidectomy combined with lateral lymph node dissection. Clinicopathological characteristics were evaluated, and the occurrence and pattern of LLNM were analyzed. Univariate and multivariate Logistic regression analyses were used to assess the factors associated with LLNM. A nomogram model was established based on the results, and the receiver operating characteristic(ROC)curve was utilized to evaluate the models accuracy. Results LLNM was most commonly observed in area-Ⅲ(38.1%), and the two-segment metastasis pattern was the most prevalent(42.2%). There was no significant difference in the pattern of LLNM when the lesions were located in different areas of the gland(P>0.05). Multivariate Logistic regression analysis revealed that the location of the lesion, levels of free triiodothyronine(FT3), thyroid-stimulating hormone(TSH), thyroid peroxidase antibodies(TPOAB), and the number of central lymph node metastasis(CLNM)were independent risk factors for LLNM. The area under the curve of the nomogram prediction model is 0.851, indicating a high level of diagnostic accuracy for the established model. Conclusion The nomogram model, incorporating clinicopathological and ultrasonic characteristics, and laboratory results(the number of CLNMs, location of the lesion, FT3, TSH, TPOAB levels), proves to be effective in predicting LLNM in PTCs larger than 10 mm and holds promise for clinical application.

Key words: Papillary thyroid carcinoma, Lateral lymph node metastasis, Central lymph node metastasis, Thyroid stimulating hormone, Thyroid peroxidase antibody, Free triiodothyronine

中图分类号: 

  • R736.1
[1] 刘燕,曹广磊,陈丽.超声引导下细针穿刺和BRAFV600E分子检测在甲状腺癌诊断中的价值[J].山东大学学报(医学版), 2022, 60(10): 57-61. LIU Yan, CAO Guanglei, CHEN Li. Ultrasound-guided fine needle aspiration biopsy and BRAFV600E molecular detection in the diagnosis of thyroid cancer[J]. Journal of Shandong University(Health Sciences), 2022, 60(10): 57-61.
[2] Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.
[3] Heng Y, Feng S, Yang Z, et al. Features of lymph node metastasis and structural recurrence in papillary thyroid carcinoma located in the upper portion of the thyroid: a retrospective cohort study[J]. Front Endocrinol, 2022,12: 793997. doi:10.3389/fendo.2021.793997.
[4] Feng JW, Ye J, Hong LZ, et al. Nomograms for the prediction of lateral lymph node metastasis in papillary thyroid carcinoma: Stratification by size[J]. Front Oncol, 2022,12: 944414. doi:10.3389/fonc.2022.944414.
[5] Gao L, Li X, Xia Y, et al. Large-volume lateral lymph node metastasis predicts worse prognosis in papillary thyroid carcinoma patients with N1b[J]. Front Endocrinol,2022,12: 815207. doi:10.3389/fendo.2021.815207.
[6] 张宏,钱林学.甲状腺乳头状癌超声特征预测侧颈区淋巴结转移的研究[J].中国医药生物技术, 2023, 18(4): 344-349. ZHANG Hong, QIAN Linxue, Predictive value of ultrasonographic features of papillary thyroid carcinoma nodules for lateral cervical lymph node metastasis[J]. Chinese Medicinal Biotechnology, 2023, 18(4): 344-349.
[7] Song WJ, Um IC, Kwon SR, et al. Predictive factors of lymph node metastasis in papillary thyroid cancer[J]. PLoS One, 2023,18(11): e0294594. doi:10.1371/journal.pone.0294594.
[8] 邵长秀,贺青卿,庄晓璇,等.934例甲状腺微小乳头状癌颈淋巴结部位转移及危险因素[J].山东大学学报(医学版), 2023, 61(2): 57-64. SHAO Changxiu, HE Qingqing, ZHUANG Xiaoxuan. Patterns and risk factors of cervical lymph node metastasis in 934 cases of papillary thyroid microcarcinoma[J]. Journal of Shandong University(Health Sciences), 2023, 61(2): 57-64.
[9] Liu JJ, Liu LP, Zhang YJ, et al. Analysis of characteristics microvessel density of thyroid malignant and benign nodules on contrast-enhanced ultrasonography[J]. AUTD, 2018, 2(3): 167-172.
[10] 徐震纲,刘绍严.分化型甲状腺癌颈侧区淋巴结清扫专家共识(2017版)[J].中国实用外科杂志, 2017, 37(9): 985-991.
[11] Caliskan O, Unlu MT, Yanar C, et al. Predictive factors affecting the development of lateral lymph node metastasis in papillary thyroid cancer[J]. Sisli Etfal Hastan Tip Bul, 2023, 57(3): 312-319.
[12] White C, Weinstein MC, Fingeret AL, et al. Is less more? a microsimulation model comparing cost-effectiveness of the revised American Thyroid Associations 2015 to 2009 guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer[J]. Ann Surg, 2020, 271(4): 765-773.
[13] Takami H, Ito Y, Okamoto T, et al. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons[J]. World J Surg, 2011, 35(1): 111-121.
[14] Lai SW, Fan YL, Zhu YH, et al. Machine learning-based dynamic prediction of lateral lymph node metastasis in patients with papillary thyroid cancer[J]. Front Endocrinol, 2022, 13: 1019037. doi: 10.3389/fendo.2022.1019037.
[15] Arishi AA, Abualhana F, Sferra J. Horners syndrome following thyroid surgery[J]. Cureus, 2023,15(9): e45825. doi:10.7759/cureus.45825.
[16] Kim SK, Park I, Hur N, et al. Patterns, predictive factors and prognostic impact of multilevel metastasis in N1b papillary thyroid carcinoma[J]. Br J Surg, 2017, 104(7): 857-867.
[17] Feng Y, Min Y, Chen H, et al. Construction and validation of a nomogram for predicting cervical lymph node metastasis in classic papillary thyroid carcinoma[J]. J Endocrinol Invest, 2021, 44(10): 2203-2211.
[18] Feng JW, Hong LZ, Wang F, et al. A nomogram based on clinical and ultrasound characteristics to predict central lymph node metastasis of papillary thyroid carcinoma[J]. Front Endocrinol, 2021,12: 666315. doi:10.3389/fendo.2021.666315.
[19] So YK, Kim MJ, Kim S, et al. Lateral lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis for prevalence, risk factors, and location[J]. Int J Surg, 2018, 50: 94-103. doi: 10.1016/j.ijsu.2017.12.029.
[20] Liu XN, Duan YS, Yue K, et al. The optimal extent of lymph node dissection in N1b papillary thyroid microcarcinoma based on clinicopathological factors and preoperative ultrasonography[J]. Gland Surg, 2022,11(6): 1047-1056.
[21] Gong J, Zhu B, Liu W, et al. Risk factors for lymph node metastasis in papillary thyroid carcinoma: a retrospective study[J]. Horm Metab Res, 2023, 55(5): 315-322.
[22] Wang Y, Deng C, Shu X, et al. Risk factors and a prediction model of lateral lymph node metastasis in cN0 papillary thyroid carcinoma patients with 1-2 central lymph node metastases[J]. Front Endocrinol, 2021, 12: 716728. doi: 10.3389/fendo.2021.716728.
[23] Dolidze DD, Shabunin AV, Mumladze RB, et al. A narrative review of preventive central lymph node dissection in patients with papillary thyroid cancer- A necessity or an excess[J]. Front Oncol, 2022,12: 906695. doi:10.3389/fonc.2022.906695.
[24] Dou Y, Hu D, Chen Y, et al. PTC located in the upper pole is more prone to lateral lymph node metastasis and skip metastasis[J]. World J Surg Oncol, 2020, 18(1):188. doi:10.1186/s12957-020-01965-x.
[25] 何小景,刘洋,刘华朋,等.血清甲状腺激素及抗体水平与分化型甲状腺癌风险等级的关系[J].临床医学, 2024, 44(1): 36-38.
[26] Xu B, Gu SY, Zhou NM, et al. Association between thyroid stimulating hormone levels and papillary thyroid cancer risk: a meta-analysis[J]. Open Life Sci, 2023, 18(1): 20220671. doi: 10.1515/biol-2022-0671.
[27] Mao A, An N, Wang J, et al. Association between preoperative serum TSH and tumor status in patients with papillary thyroid microcarcinoma[J]. Endocrine, 2021, 73(3): 617-624.
[27] Xiang Y, Xu Y, Bhandari A, et al. Serum TSH levels are associated with postoperative recurrence and lymph node metastasis of papillary thyroid carcinoma[J]. Am J Transl Res, 2021,13(6): 6108-6116.
[29] Huang D, Zhi J, Zhang J, et al. Relationship between thyroid autoantibodies and recurrence of papillary thyroid carcinoma in children and adolescents[J]. Front Oncol, 2022, 12: 883591. doi: 10.3389/fonc.2022.883591.
[30] Yang Y, Liu J, Shi X, et al. Clinical and pathological characteristics of patients with papillary thyroid carcinoma coexisting with Hashimotos Thyroiditis: a retrospective cohort study[J]. Cancer Control, 2023, 30: 10732748231199647. doi:10.1177/10732748231199647.
[31] Huang K, Gao N, Bian D, et al. Associations of BRAFV600E, clinical pathology and imaging factors with the recurrence rate of papillary thyroid microcarcinoma[J]. Exp Ther Med, 2020, 20(6): 243. doi: 10.3892/etm.2020.9373.
[32] Chang Q, Zhang J, Wang Y, et al. Nomogram model based on preoperative serum thyroglobulin and clinical characteristics of papillary thyroid carcinoma to predict cervical lymph node metastasis[J]. Front Endocrinol, 2022,13: 937049. doi: 10.3389/fendo.2022.937049.
[33] Liu S, Liu C, Zhao L, et al. A prediction model incorporating the BRAFV600E protein status for determining the risk of cervical lateral lymph node metastasis in papillary thyroid cancer patients with central lymph node metastasis[J]. Eur J Surg Oncol, 2021, 47(11): 2774-2780.
[1] 刘馨,侯新国,刘继东,赵红霞. 伴TSHR基因突变促甲状腺激素抵抗综合征1例[J]. 山东大学学报 (医学版), 2023, 61(10): 113-116.
[2] 张薇薇,华芳,梁超帅,褚苗苗,孙嘉忆,Frank Zaucke,辛玮. 促甲状腺激素通过抗炎蛋白CTRP3促进软骨细胞分化[J]. 山东大学学报 (医学版), 2022, 60(10): 1-8.
[3] 王余余,高丽,陈少华. 94例2型糖尿病患者急性脑梗死后认知障碍与甲状腺功能的关联性[J]. 山东大学学报 (医学版), 2020, 58(5): 56-61.
[4] 石飞,潘翔,杨见明. 106例甲状腺乳头状癌患者行甲状腺全切手术后生存质量分析[J]. 山东大学学报 (医学版), 2020, 58(5): 87-92.
[5] 于娜,郭情情,孙梅,盛燕,马增香,秦莹莹. 甲状腺癌术后行IVF/ICSI-ET助孕临床结局[J]. 山东大学学报 (医学版), 2018, 56(9): 54-58.
[6] 张琳,李敬,王泽,张江涛,马增香,石玉华. 多囊卵巢综合征患者促甲状腺激素对血糖、血脂的影响[J]. 山东大学学报（医学版）, 2017, 55(1): 80-84.
[7] 郝战宇,李波. 桥本甲状腺炎合并甲状腺乳头状癌的临床及病理学特征[J]. 山东大学学报（医学版）, 2016, 54(6): 73-77.
[8] 申妍,左常婷. 济南地区正常妊娠妇女各期甲状腺功能指标的参考值范围评估[J]. 山东大学学报（医学版）, 2016, 54(5): 34-38.
[9] 王琦1,2，于春晓3，高聆1，赵家军3，曹铭锋3. 1-7554.0.2013.611促甲状腺激素调节肝脏AMPKα Thr 172而非Ser 173的磷酸化[J]. 山东大学学报（医学版）, 2014, 52(6): 22-27.
[10] 王付颖1,刘晓萌2,董庆玉2,梁翠格2,杜文华2,王月丽2,李文侠2,高冠起2. Graves病患者131I治疗后TRAb变化与早发甲减的相关性[J]. 山东大学学报（医学版）, 2014, 52(6): 55-57.
[11] 张雯雯1，张艳玲1，王杰1，高聆2，于春晓1，阎慧丽1，徐进1. 促甲状腺激素对破骨细胞分化的影响[J]. 山东大学学报(医学版), 2013, 51(4): 6-10.
[12] 李亚男1，蒋玲1，胡秀慧1，张晓黎1，李杰2. 碘酸钾和双酚A对甲状腺乳头状癌细胞增殖的影响[J]. 山东大学学报(医学版), 2013, 51(3): 52-57.
[13] 李建周，刘欣，张凌云，金勇君. 术前血清TSH浓度与分化型甲状腺癌的相关性研究[J]. 山东大学学报(医学版), 2011, 49(1): 10-13.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发